Free Trial Information
BioCentury | Aug 15, 2020
Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

CanSino vaccine stops COVID-19 in mice, ferretsMice given a single intranasal immunization with Ad5-nCoV from CanSino Biologics Inc. (HKEX:6185; Shanghai:688185) and then challenged with mouse-adapted SARS-CoV-2 had no detectable virus in the lungs and nose...
Read More
BioCentury | Jan 13, 2020
Company News

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease. Monday’s deal is Biogen’s second in...
Read More
BioCentury | Feb 5, 2019
Distillery Therapeutics

Cancer

...cancer In vitro and cell culture studies identified an aminothiazole-based negative allosteric modulator (NAM) of CSNK2...
...bound an allosteric site on CSNK2 with a K i of 0.18 μM and inhibited CSNK2...
...Pharmaceuticals Inc. has a CSNK2 inhibitor in preclinical testing for brain cancer. TARGET/MARKER/PATHWAY: Casein kinase 2 (CSNK2; CKII...
Read More
BioCentury | Apr 13, 2018
Clinical News

ProMIS identifies new beta amyloid epitope to treat AD

Researchers at the University of British Columbia reported preclinical data showing that PMN300 decreased soluble beta amyloid aggregates and neurotoxicity in the brain in two mouse models of Alzheimer's disease. In a paper published in...
Read More
BioCentury | Jan 12, 2018
Company News

Exelixis, StemSynergy in CSNK1A activator deal

Exelixis Inc. (NASDAQ:EXEL) and StemSynergy Therapeutics Inc. (Miami, Fla.) partnered to discover and develop compounds targeting casein kinase 1 alpha (CSNK1A; CKI-alpha) to treat cancer. The partners will conduct preclinical and clinical studies of compounds...
Read More
BioCentury | Aug 17, 2017
Translation in Brief

Stopping the invasion

...casein kinase 2 ( CSNK2 ; CKII), a negative regulator of the IRF3 pathway. Pharmacological inhibition of CSNK2...
...xenograft mouse model (see Distillery ). Senhwa Biosciences Inc. (TPEx: 6492) has CX-4945, an oral CSNK2...
...said that because invading cells are typically not proliferating cells, and vice versa, using a CSNK2...
Read More
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...INDICATION: Brain cancer Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could...
...vector. In three additional patient-derived GBM cell lines co-cultured with the mouse brain slices, the CSNK2...
...CSNK2, in preclinical testing for solid tumors. TARGET/MARKER/PATHWAY: Interferon regulatory factor 3 (IRF3); casein kinase 2 (CSNK2; CKII...
Read More
BioCentury | Jul 18, 2017
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, in vitro , cell culture and mouse studies identified a benzamide-based CSNK1A activator that could help treat Wnt signaling-driven colorectal cancer. In colorectal cancer patients, low tumor levels of CSNK1A were...
Read More
BioCentury | Feb 28, 2017
Distillery Therapeutics

Neurology

...doi:10.1038/ncomms14405 CONTACT: Dennis J. Thiele, Duke University School of Medicine, Durham, N.C. email: dennis.thiele@duke.edu Hongjiang Li Duke University Casein kinase 2...
Read More
BioCentury | Aug 4, 2016
Targets & Mechanisms

Cereblon ambition

Most anti-cancer strategies aim to block overactive proteins by directly inhibiting their activity, but a growing number of companies are developing ways to tag the proteins for destruction by recruiting the enzymes that shuttle them...
Read More
Items per page:
1 - 10 of 43